



Indiana State
Department of Health

LONG TERM CARE NEWSLETTER

**ISDH Long Term Care
Newsletter
Issue 2019-04
July 11, 2019**

Today's Issue

Long Term Care Updates

- Directed In-service Training
- Qualified Medication Aide – Insulin Administration
- Transfer / Discharge – Ombudsman Office
- Tuberculin Skin Test – Aplisol Shortage

Long Term Care Updates

Directed In-service Training Information

Directed in-service training is one of the remedies the State or Regional office can select when it finds a facility out of compliance with Federal requirements. Directed in-service training may be used when education is likely to correct the deficiencies and help the facility achieve substantial compliance. This remedy requires the staff of the facility to attend an in-service training program that provides basic knowledge to achieve and remain in compliance with Federal requirements.

The Indiana State Department of Health Long Term Care Division has received guidance from Centers for Medicare & Medicaid Services (CMS) Regional Office V that a facility's corporate specialist may complete the directed in-service training. Therefore, the nurse consultants, social service specialists, or registered

dietitians from the corporate office are able to conduct the directed in-service training.

Additional information is available: [State Operation Manual – Chapter 7 -7502 – Directed In-Service Training.](#)

Qualified Medication Aide – Insulin Administration

House Enrolled Act No. 1652 (HEA 1652) will allow a qualified medication aide (QMA) to administer insulin following the completion of an approved training module and passing a written and practical examination effective January 1, 2020. The Indiana State Department of Health is currently developing an education and training module to meet the requirements of HEA 1652. The training module will be available on January 1, 2020. This training is optional for QMAs.

Additional information is available: [House Enrolled Act No. 1652](#)

Transfer / Discharge – Ombudsman Office

Lynn Clough, Director, Indiana State Long-Term Care Ombudsman Program, has requested the following information be shared with long term care facilities. Centers for Medicare & Medicaid Services (CMS) require facilities to notify the Long-Term Care Ombudsman of resident transfers and discharges. The attached letter and forms provide information to assist with proper notification to the Ombudsman in Indiana.

[Nursing Home Administrator Letter](#)
[Transfer/Discharge Decision Tree](#)
[Monthly Transfer/Discharge Notification Form](#)

Any questions please contact Ombudsman office at 317.232.7134 or email ltpviderservices@isdh.in.gov.

Tuberculin Skin Test – Aplisol Shortage

The Centers for Disease Control and Prevention (CDC) is expecting a 3–10 month nationwide shortage of Aplisol. Aplisol is one of two purified-protein derivative (PPD) tuberculin antigens licensed for use in performing tuberculin skin test (TST). The manufacturer notified the CDC that the anticipated interruption of supply of Aplisol 5 mL (50 multidose vials) in June 2019, followed by an

interruption of the supply of Aplisol 1 mL (10 multidose vials) in November 2019. This time frame is the manufacturer's current estimate and is subject to change.

There are two FDA-approved PPD tuberculin antigen products available in the United States for use in performing TSTs: Tubersol (Sanofi-Pasteur) and Aplisol. In controlled studies, the concordance between the two products is high.

The Indiana State Department of Health, Division of Long Term Care guidance at this time is the substitution of Tubersol for Aplisol for TST. Additional guidance will be issued should the shortage affect both Tubersol and Aplisol.

Additional information: [Nationwide Shortage of Tuberculin Skin Test Antigens: CDC Recommendations for Patient Care and Public Health Practice](#)